 PLANO, Texas--BUSINESS WIRE--Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata, the Company, our, us, or we, a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Companys business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open. 